Theriva Biologics achieved target enrollment of 92 evaluable patients in its VIRAGE Phase 2b trial of VCN-01 for metastatic pancreatic ductal adenocarcinoma (PDAC). The company is exploring potential expansion into a Phase 3 registrational trial, leveraging its Orphan Drug and Fast Track designations. Additionally, Theriva received European Orphan Medicinal Product Designation and FDA Rare Pediatric Disease Designation for VCN-01 in retinoblastoma treatment.For Q3 2024, Theriva reported a net loss of $7.7 million compared to $3.3 million in Q3 2023. Research and development expenses decreased 32% to $2.7 million, while general and administrative expenses increased to $2.3 million. The company recorded impairment charges of $2.8 million for in-process R&D and goodwill.Cash and cash equivalents stood at $16.4 million as of September 30, 2024, down from $23.2 million at year-end 2023. The company secured manufacturing funding from the Spanish Government's National Knowledge Transfer Program and placed second in Merck KGaA's EMEA Advance Biotech Grant competition.

Theriva Biologics achieved target enrollment of 92 evaluable patients in its VIRAGE Phase 2b trial of VCN-01 for metastatic pancreatic ductal adenocarcinoma (PDAC). The company is exploring potential expansion into a Phase 3 registrational trial, leveraging its Orphan Drug and Fast Track designations. Additionally, Theriva received European Orphan Medicinal Product Designation and FDA Rare Pediatric Disease Designation for VCN-01 in retinoblastoma treatment.For Q3 2024, Theriva reported a net loss of $7.7 million compared to $3.3 million in Q3 2023. Research and development expenses decreased 32% to $2.7 million, while general and administrative expenses increased to $2.3 million. The company recorded impairment charges of $2.8 million for in-process R&D and goodwill.Cash and cash equivalents stood at $16.4 million as of September 30, 2024, down from $23.2 million at year-end 2023. The company secured manufacturing funding from the Spanish Government's National Knowledge Transfer Program and placed second in Merck KGaA's EMEA Advance Biotech Grant competition.